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Abstract
Background: To evaluate if white matter lesions (WML) on MRI can be a potential marker for onabotulinum toxin A
(Botox®) treatment success in migraine, given the limited response rate and high costs per treatment.
Methods: Retrospective data base and MRI analysis of 529 migraineurs who received Botox® between 2002 and
2009. Responders were defined as patients who underwent three or more treatments, whereas non-responders
had only one or two treatments. MRIs were analysed on axial T2 and coronar FLAIR (fluid attenuated inversion
recovery) sequences for the presence of WML. Statistical analysis was done with the Chi-Square-Test and the
Mann–Whitney-U-Test.
Results: Of 529 Botox® treated migraineurs, 111 patients had a MRI. Of these 111 patients, 47 were responders, 64
non-responders to Botox®. Response rate to Botox® in migraineurs with WML was 55.3%, in migraineurs without
WML 44.7%. In the investigated items “age”, “age at onset”, “gender”, “attack duration”, “frequency”, “aura”, “WML”,
“size of WML”, we found no statistical significant difference between the two groups. 55% of the responders and
50% of the non-responders showed WML. All WML were located supratentorially, anteriorly, mostly of small size
(3–5 mm).
Conclusion: WML on MRIs cannot serve as a marker to predict a positive response to Botox®.
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Background
Migraine is a primary headache disorder. According to
the WHO, the lifetime prevalence of migraine in Europe
and North America is 6% in men and 15-18% in women
for one year (Natoli et al. 2010; Leonardi & Mathers
2000). Several large longitudinal studies regarding mi-
graine prevalence exist, the AMPP (American Migraine
Prevalence and Prevention) and the Norwegian HUNT
study (Munakata et al. 2009; Linde et al. 2010), indica-
ting a slight increase in migraine over the last years. Im-
proved prevention treatment is needed, with higher
efficacy, causing fewer, at best no side-effects.
An approach for this kind of prevention, might be
the use of onabotulinum toxin A (Blumenfeld 2003).
Botulinum toxin is used since the early 70s for medical
purposes, first to correct strabism and later to treat
focal dystonias, spasticity, hyperhidrosis and many other
disorders (Lukban et al. 2009; Rosales & Chua-Yap 2008;
Binder et al. 2000). Since 2010, based on the two
PREEMPT-studies (Phase III Research Evaluating Mi-
graine Prophylaxis Therapy), onabotulinum toxin A is
registered for the indication chronic migraine in the
USA and since 2011 in Great Britain and the European
Community.
Botox® (Allergan, Inc., Irvine, CA) mediates its postu-
lated mechanism of action in migraine by inhibiting the
release of nociceptive agents, such as glutamate, sub-
stance P, calcitonin gene-related peptide and acetylcho-
line (Durham & Cady 2004; Gupta et al. 2011a,b). The
advantage of a treatment with Botox® is the good to-
lerability, the lack of side-effects and the therapeutic ef-
fect over three to six months. The success rate varies
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between 30% and 50% (Dodick et al. 2010). The main
disadvantage are the high costs of one Botox® treatment
that are mostly not reimbursed. However, patients with
chronic migraine, suffering predominantly from unilat-
eral headache, presence of scalp allodynia and pericra-
nial muscle tenderness, seemed to show a rather good
response (Blumenfeld et al. 2010a; Robertson & Garza
2012).
It is known that subjects with migraine are at higher
risk of having WML on the MRI than those without mi-
graine (Mathew et al. 2008). Several studies, such as the
CAMERA (Cerebral Abnormalities in Migraine, an Epi-
demiologic Risk Analysis) study showed that migrai-
neurs, notably those with aura, had a higher prevalence
of subclinical infarcts in the posterior circulation terri-
tory. Higher risk of lesions was present in those with
higher attack frequencies or longer migraine history
(Richard et al. 2004). The etiology of the WML remains
unclear. A possible pathological mechanism is ischemia,
maybe mediated through cortical spreading depression
that causes disruption of the blood brain barrier (BBB)
through a matrix metalloproteinase-9-dependent cascade
mechanism, which may result in local tissue damage
(Woods et al. 1994; Ayata et al. 2006).
The aim of our study was to investigate, if WML on
MRI scans can serve as a marker to evaluate in advance
the success of a treatment with Botox® in migraineurs.
We focused on the two groups “responders” and “non-
responders” to Botox® and tried to find some predicting
differences in these two groups regarding success rate to
Botox®.
The association between Botox® and WML in the MRI
has until now not yet been studied.
Methods
Our center is specialised in the diagnosis and treatment
of headache disorders with 2.000 new headache patients
per year and is experienced in the use of Botox® for mi-
graine since 2002.
Clinical parameters
In a retrospective fashion, 529 patients were identified
from our database between 1 January 2002 and 1 July
2009, having received Botox® treatment for migraine. Of
these 529 patients, 111 had a MRI scan. Data were col-
lected of these 111 patients. The database contained
name, gender, date of birth , migraine history, chroni-
fication, number of Botox® treatments, date of MRI scan,
number, localization and size of WML.
Responders to Botox® were defined by us as patients
who underwent three or more treatments, non-respon-
ders one or two treatments.
The Botox® therapy followed the recommendations of
the PREEMPT trials (Neema et al. 2009). However, we
used a smaller dose of Botox® (100 IU versus 155 IU),
mainly because of the costs that are predominantly paid
by the patients themselves. And the application sites
with the dose of Botox® for each muscle were slightly di-
vergent from the PREEMPT paradigm. They are shown
in Table 1.
Imaging
MRIs were available electronically from the hospital
radiology system. All scans had been performed on 1.5
Tesla or 3 Tesla MR tomographs, according to a stan-
dardized migraine protocol. 58 MRIs with reported
WML and 53 MRIs with no reported WML were ana-
lysed, on coronar FLAIR sequences and on axial T2
sequences, in maximal 5 mm slices. WML were clas-
sified as small (3–5 mm), medium (6–9 mm) or large
(>10 mm). Total number of lesions was recorded. The
distribution was classified in supratentorial or infraten-
torial. If supratentorial, in anterior or posterior, with cut
at the middle of corpus callosum.
Each WML analysis was performed independently by
two neurologists, each blinded to the history of the pa-
tient. In case of disagreement between the two readers, a
consensus was achieved by discussion.
Statistical analysis followed the statistical program
SPSS (Superior Performing Software System). The Chi-
Square-Test was applied for the items gender, duration,
frequency (episodic vs. chronic), aura and non-parame-
tric values such as age, age at onset, WML, were ana-
lyzed by the Mann–Whitney-U-Test.
Results and discussion
Clinical parameters
In the current group of 111 Botox® treated patients, 47
have been responders and 64 non-responders. We found
in none of the investigated parameters a statistical signifi-
cance to characterize or distinct responders from non-
responders, details are shown in Table 2. Both groups have
Table 1 Botox® scheme for migraine at our center
Right injections IU Left injections IU Total IU
Muscle
Frontal 2 2.5 2 2.5 10
Corrugator 1 2.5 1 2.5 5
Procerus 1 2.5 1 2.5 5
Temporal 3 5 3 5 30
Suboccipital 1 2.5 1 2.5 5
Semispinal 1 2.5 1 2.5 5
Splenius 1 2.5 1 2.5 5
Trapezius 6 2.5 6 2.5 30
Occipital 1 2.5 1 2.5 5
Total 17 25 17 25 100
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been in the middle ages, with disease onset as young
adults. Women were predominant in both groups. The
presence of aura was not predictive to a Botox® response,
neither the type of migraine “episodic” or “chronic”.
Imaging
The analyzed WML in the MRIs followed no pattern to
permit a conclusion for a positive response to a Botox®
treatment. WML were absent in 45% of the responders,
present in 55%. In the non-responders, WML were
absent in 50%, present in 50%. Mean lesion load of
small-size- WML in responders was 2.3 per person, in
non-responders 2.9 per person. Mean lesion load of
medium-size- WML was 0.2 in both groups per person
and of large-size- WML was 0.02 per person in respon-
ders and 0.03 per person in non-responders. Figure 1
shows the typical distribution of WML in our Botox®-
migraine-population on MRI, in responders and non-
responders. They are located supratentorially and anteri-
orly, mostly of small size.
The aim of our study was to find a marker of response
to Botox®, in order to optimize treatment of migraine pa-
tients in clinical practice.
The response rate to Botox® in the treatment of mi-
graine is generally in a range of 30% to 50% (Blumenfeld
et al. 2010a). In our study, the response rate to Botox® in
migraineurs with WML was 55.3%, in migraineurs with-
out WML 44.7%. Our definition for a response to Botox®
was pragmatically by assigning migraine patients to the
number of Botox® treatments, so that responders were
defined as migraineurs with three or more treatments
and non-responders as migraineurs with one or two
treatments. This endpoint has not been used before and
is a simplified response criterion that is easily generated
even in a retrospective analysis. The more sophisticated
endpoints, usually generated in migraine prophylaxis
studies, such as PREEMPT, are typically not obtainable
in clinical practice. Nevertheless, our response rates are
in the range of those in standard clinical trials, such as
the pooled analysis in the two PREEMPT studies, with
a 50% response rate of Botox® against placebo. This
response rate was measured by reduction in mean fre-
quency of headache days, headache episodes and im-
provement of patients’ functioning, vitality, psychological
distress and overall, quality of life (Blumenfeld et al.
2010a). In our study, the gain of quality of life was
assessed in the regular clinical follow-ups of the pa-
tients and documented in the patients’ history, but
not by specific questionnaires or daily phone calls to
a trial center.
Since WML are associated with the so called burden
of disease in migraine sufferers, we attempted to analyze
our migraine Botox® population with respect to WML as
a possible predictor. The clinical importance of WML
on MRI scans in different medical conditions has been
Table 2 Responders versus non-responders
Responders
to Botox®
Non-responders
to Botox®
p-value
Age (mean) 47 52 0.07 ns
Age at onset (mean) 21 21 0.912 ns
Gender (m/f) % 15/85 23/77 0.265 ns
Lifetime migraine (years) 26 31 0.255 ns
Chronic migraine % 66 62.5 0.708 ns
Aura % 60 52 0.402 ns
WML % 55 50 0.579 ns
WML small (mean per
person)
2.3 2.9 0.897 ns
WML medium (mean
per person)
0.2 0.2 0.875 ns
WML large (mean per
person)
0.02 0.03 0.750 ns
Figure 1 Coronar brain MRI slices (FLAIR), in (a), on the left side, with one WML in a responder and in (b), on the right side, with three
WML in a non-responder.
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shown before. WML serve as a biomarker for an in-
creased risk of cerebrovascular events and predict a
higher risk of stroke, dementia and death (Bigal 2010).
However, in our study, the comparison of the two
groups Botox®-responders and Botox®-non-responders
showed no difference in the investigated items. So, our
initial hypothesis, that white matter lesions could serve
as a biomarker to predict a better response to Botox® in
migraine treatment was disproved. The appearance of
WML is not related to success or failure to a Botox®
treatment, nor can presence or absence of WML predict
the outcome of a treatment with Botox®.
In general, the meaning of these WML in migraineurs
is unclear (Colombo et al. 2011) and the clinical import-
ance often remains meaningless. However, before focus-
sing on details in the discussion of WML, some basics
have to be taken into account. Steady improvements of
MRI techniques, with increasing use of 3T MRI, even
7T in some centers, instead of 1.5T MRI, show differ-
ences in the outcome of WML. So, for example in the
study of Neema et al., realized in healthy volunteers
(Neema et al. 2009), WML were seen three times more
on FLAIR sequences of 3T MRIs than on FLAIR se-
quences of 1.5T MRIs. Sometimes, Virchow-Robin (VR)
spaces may contribute to some confusion in analyzing
WML. They have to be well distinguished from WML.
VR spaces surround the walls of vessels and course from
the subarachnoid space to the brain parenchyma. With
advancing age, they become more frequent and larger in
size (>2 mm). The signal intensity of VR spaces is identi-
cal to that of cerebrospinal fluid on all MR sequences.
So, the FLAIR sequence is ideal, to distinct VR spaces
from WML in difficult situations (Kwee & Kwee 2007).
In migraine, WML are more often seen in chroni-
fication (Schwedt & Dodick 2009; Debette & Markus
2010). So, chronic migraineurs with a longer duration of
migraine and a higher attack frequency might contribute
to a higher amount of WML (Schmitz et al. 2008). This
is confirmed in our study, where WML appear to a
higher amount in chronic migraine and less in episodic
migraineurs. These findings are consistent with the con-
cept of migraine chronification that can be seen on dif-
ferent levels, first in clinical transformation (increased
frequency), physiologic transformation (allodynia, central
sensitization) and, finally, anatomic progression with
presence of WML (Aguggia & Saracco 2010; Bigal &
Lipton 2008).
The distribution of WML in migraine has already been
a subject of interest in various studies. Especially in
migraine with aura patients, lesions in the deep white
matter of the brain were detected, mainly in the frontal
lobes. The type of aura symptoms did not correlate with
the location of WML in the brain (Rossato et al. 2010).
However, in some studies like the CAMERA-study,
subclinical brain infarcts were located exclusively in the
posterior circulation territory, especially in the cerebel-
lum. The authors assumed an ischaemic origin through
hypoperfusion and/or embolisms. Right-left-shunts of
persistent foramen ovale as potential origin were not in-
vestigated. The lesions had a diameter of up to 7 mm.
These lesions were mostly seen in female migraine with
aura patients (8%) with higher attack frequency (Kruit
et al. 2009). In the study of Scher et al., investigating the
association of migraine headache and brain infarcts, an
increased risk of cerebellar infarcts in middle aged
women with migraine with aura was found (Scher et al.
2009). In our study, all WML were located supraten-
torially and anteriorly, mostly of small size. However,
we did not find any difference in responders or non-
responders concerning age, gender or aura.
The etiology of WML remains unclear. An ischemic
origin has been postulated in most publications (Bigal
2010). It could be conceivable, that damage to the white
matter may also happen by excitatory neurotransmitters,
especially glutamate and ATP, which can result also
in ischemic lesions. A disruption of glutamate homeo-
stasis can be deleterious to neurons and oligodendro-
glia (Matute 2011). Furthermore a glutamate induced
activation of phospholipase A2, has been attributed to
play a major role in the neurotoxicity encountered
during brain ischemia (Khanna et al. 2010).
In summary, different pathological mechanisms can
be responsible for the presence of WML. First, an in-
flammatory origin, seen in autoimmune disorders (for
example, multiple sclerosis, vasculitis (Chen et al. 2010),
lupus erythematodes) or in infectious diseases like
borreliosis. Second, an ischemic origin, like in cerebro-
vascular diseases (Bonati et al. 2005) such as brain in-
farcts or inherited metabolic disorders like Fabry disease.
Third, even “older age” without presenting any cerebro-
vascular risk factors is enough for developping WML, as
shown in a study by Chowdhury et al. (Chowdhury
2011), including patients with a mean age of 61.7 years.
Fourth, vascular dementias, Alzheimer’s disease and ce-
rebral amyloid angiopathy can contribute to WML.
Deposition of amyloid in the arteries, resulting in hy-
poperfusion can result in WML. In these conditions, the
leading clinical symptoms of the WML are cognitive de-
cline and symptomatic depressive states. Fifth, in mood
disorders, especially bipolar disorders, WML are often
present. They have been associated with the emotional
and cognitive symptoms in bipolar disorder, caused by
disruption of the fibers from the amygdala to other brain
regions, leading to the presence of WML. It has even
been discussed that WML could serve as a biomarker
for the disturbances in mood and cognition in bipolar
disorder (Benedetti et al. 2011; Gunde et al. 2011). Sixth,
an cardioembolic mechanism of WML, caused by a
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right-to-left-shunt from a persistent foramen ovale,
atrial fibrillation, can be a possible etiologic mecha-
nism (Park 2011).
But not only the origin of the WML is heterogeneous,
but as well their evolution. So, a progression of WML in
healthy elderly people (mean age 71 years) was demon-
strated in a study over three years (Sachdev et al. 2007).
In contrast, a case report of a chronic migraine patient,
showed a disappearance of WML in control MRIs over
5 months (Rozen 2010).
The precise mechanism of Botox® as headache prophy-
laxis is not fully elucidated, human and animal studies
have shown that Botox® blocks release of neurotransmit-
ters associated with the genesis of pain. The heavy chain
of botox A binds to a ganglioside receptor in the plasma
membrane of the presynaptic nerve terminal. This leads
to receptor mediated endocytosis of the neurotoxin. The
heavy and the light chain of botox are cleaved. The light
chain translocates to the cytosol and cleaves the C-
terminal of the SNAP-25 protein. This inhibits SNARE
complex formation and therefore inhibits neurotransmit-
ter release (Blumenfeld et al. 2010b), such as substance
P, calcitonin gene-related peptide (Blumenfeld et al.
2010a) and glutamate from the peripheral termini of pri-
mary afferents. Botox® inhibits peripheral signals to the
central nervous system and thus indirectly inhibits cen-
tral sensitization (Robertson & Garza 2012).
Our study shows several limitations, such as the retro-
spective study design and the rather small sample size.
As well, the quantity of available MRIs might be too
small, not everyone of our migraine patients between
2002 and 2009 underwent a MRI. Our definition of
responders and non-responders, despite being very prag-
matically and close to the clinical context, may contribute
to some false results: first, patients in the non-responder
group (one or two treatments) could be “cured” of mi-
graine for a certain time. Second, patients with a very long
treatment interval were included in the study, ending in
2009. Third, patients, corresponding to a treatment, but
unable to pay for further treatments. Some false results in
the responder group (≥ three treatments) could arise, first,
from non-responders, having tried several times Botox®.
However, more than three treatments without any sort of
response are very unlikely. Second, an initial responder
becomes a non-responder.
Improvements could be obtained by carrying on the
study in a prospective design and by realizing more
MRIs in our clinic.
Conclusions
WML on MRI scans cannot serve as a marker to predict
a positive response to Botox®. The meaning of the WML
in the migraine population remains unclear, being pro-
bably not of clinical importance. But they are often a
sign for migraine chronification and longer lifetime his-
tory of migraine. They can be seen as well in other cli-
nical conditions like cerebrovascular diseases, different
types of dementia, inflammatory diseases and bipolar de-
pression, which can be important comorbidities to mi-
graine. They have to be considered while having a look
at white matter lesions in the context of migraine.
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